(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire Avidity Biosciences for $12 billion. (Reporting by Angela Christy in Bengaluru)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post Novartis to acquire Avidity Biosciences for $12 billion appeared first on The Sunday Guardian.

See Full Page